Scholl et al examined 99 elderly patients with AML (≥60 years), of whom 23 had NPM1 mutations and 16 had the FLT3-ITD mutation.46 While NPM1 status had no impact on OS, even when restricted to the FLT3-ITD-negative subset, patients with FLT3-ITD mutations treated with curative therapy (7 patients) showed a shorter OS (634d vs. 210d, p=0.03) than those without FLT3-ITD mutations (47 patients). This evidence concerns the gene NPM1 and acute myeloid leukemia.